391906-83-5

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
3-Phenoxypyridin-2-amine is used as a building block for the construction of heterocyclic compounds, which are essential in the development of new drugs and agrochemicals. Its presence in these industries is vital for the creation of innovative and effective products.
Used in Medicinal Chemistry:
3-Phenoxypyridin-2-amine is utilized as a key intermediate in the synthesis of various medicinal compounds. Its unique structure allows for the development of drugs with specific therapeutic properties, contributing to advancements in healthcare.
Used in Materials Science:
In the field of materials science, 3-Phenoxypyridin-2-amine is employed for its potential applications in the creation of new materials with unique properties. Its versatility as a chemical intermediate makes it a valuable component in the development of innovative materials for various applications.
Used in Drug Discovery and Development:
3-Phenoxypyridin-2-amine's potential biological activity makes it a promising candidate for drug discovery and development. Researchers can use 3-Phenoxypyridin-2-aMine as a starting point to design and synthesize new drugs with targeted therapeutic effects, ultimately leading to improved treatments for various diseases and conditions.

Upstream product

• 54231-35-5 3-fuoro-2-nitropyridine 
• 108-95-2 phenol 
• 1065607-12-6 3-(2,4-dibromophenoxy)pyridin-2-amine 
• 13534-99-1 2-Amino-3-bromopyridine 
• 1435-53-6 2,4-dibromo-1-fluorobenzene 
• 16867-03-1 2-amino-3-hydroxypyridine 

Downstream Products

• 953045-12-0 5-bromo-3-phenoxypyridin-2-amine 
• 953045-99-3 1-(5-bromo-3-phenoxypyridin-2-yl)thiourea 
• 953046-12-3 3-phenoxy-5-(pyridin-2-ylthio)pyridin-2-amine 
• 1056935-12-6 1-(3-phenoxy-5-(pyridin-2-ylthio)pyridin-2-yl)thiourea 
• 1056935-04-6 1-benzoyl-3-(5-bromo-3-phenoxypyridin-2-yl)thiourea 
• 953130-90-0 5-bromo-3-phenoxy-N-(3-(piperidin-4-yl)-1,2,4-thiadiazol-5-yl)pyridin-2-amine 
• 1056935-11-5 1-benzoyl-3-(3-phenoxy-5-(pyridin-2-ylthio)pyridin-2-yl)thiourea 
• 953130-88-6 1-(4-(2-(5-bromo-3-phenoxypyridin-2-ylamino)thiazol-4-yl)piperidin-1-yl)ethanone 
• 953046-13-4 3-phenoxy-N-(3-(piperidin-4-yl)-1,2,4-thiadiazol-5-yl)-5-(pyridin-2-ylthio)pyridin-2-amine 
• 953131-47-0 1-(4-(2-(3-phenoxy-5-(pyridin-2-ylthio)pyridin-2-ylamino)thiazol-4-yl)piperidin-1-yl)ethanone 
• 953042-96-1 1-(4-(5-(3-phenoxy-5-(pyridin-2-ylthio)pyridin-2-ylamino)-1,2,4-thiadiazol-3-yl)piperidin-1-yl)ethanone 
• 953046-49-6 methyl 3-(6-(4-(1-acetylpiperidin-4-yl)thiazol-2-ylamino)-5-phenoxypyridin-3-ylthio)propanoate 
• 953131-44-7 4-(5-(3-phenoxy-5-(pyridin-2-ylthio)pyridin-2-ylamino)-1,2,4-thiadiazol-3-yl)piperidine-1-carboxamide 
• 1065604-63-8 1-(4-(2-(5-(3-hydroxypropylthio)-3-phenoxypyridin-2-ylamino)thiazol-4-yl)piperidin-1-yl)ethanone 

Relevant academic research and scientific papers

NITROGENOUS CYCLIC COMPOUND AND COLOR CHANGING FILM COMPRISING SAME

The present specification relates to a compound containing nitrogen, and a color conversion film, a backlight unit, and a display device, including the same.

Discovery and preclinical development of AR453588 as an anti-diabetic glucokinase activator

Glucose flux through glucokinase (GK) controls insulin release from the pancreas in response to high levels of glucose. Flux through GK is also responsible for reducing hepatic glucose output. Since many individuals with type 2 diabetes appear to have an inadequacy or defect in one or both of these processes, identifying compounds that can activate GK could provide a therapeutic benefit. Herein we report the further structure activity studies of a novel series of glucokinase activators (GKA). These studies led to the identification of pyridine 72 as a potent GKA that lowered post-prandial glucose in normal C57BL/6J mice, and after 14d dosing in ob/ob mice.

2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS

Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes meilitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS

Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

The studies of the intramolecular C-F---H-N hydrogen bonding using covalently-linked base pair models of F and A

Both 1H NMR and X-ray studies revealed that C-F---H-N intramolecular hydrogen bonding is not observed even in covalently-linked base pair models of F and A. These results strongly support the Kool's hypothesis.